#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5326	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1852	486.6	0	.	n	.	0	A293G	SNP	293	293	A	430	430	G	422	G	255	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5326	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1852	486.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1587	1587	T	492	T	276	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5326	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1852	486.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1321	1321	C	607	C	345	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9760	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3360	479.3	0	.	n	.	0	T695C	SNP	695	695	T	929	929	C	631	C,A	355,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9760	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3360	479.3	0	.	n	.	0	C993T	SNP	993	993	C	1227	1227	T	437	T	252	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9760	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3360	479.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2205	2205	C	469	C,A	254,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9760	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3360	479.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2279	2279	A	520	A	297	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9760	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3360	479.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2831	2831	C	560	C	315	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	9760	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3360	479.3	0	HET	.	.	.	C1345T	.	1345	1345	C	1579	1579	C	423	C,T	175,60	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	852	100.0	folP.l6.c30.ctg.1	1601	36.2	1	SNP	p	R228S	0	.	.	682	684	CGC	1014	1016	CGC	73;73;73	C;G;C	41;42;40	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	W92G	NONSYN	274	276	TGG	113	115	GGG	1;1;1	G;G;G	0;1;1	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	S97R	NONSYN	289	291	AGT	128	130	CGT	1;1;1	C;G;T	0;0;1	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	V104G	NONSYN	310	312	GTG	149	151	GGG	1;1;1	G;G;G	1;1;1	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	V105G	NONSYN	313	315	GTT	152	154	GGT	1;1;1	G;G;T	1;0;0	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	M106L	NONSYN	316	318	ATG	155	157	TTG	1;1;1	T;T;G	0;0;0	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	L110V	NONSYN	328	330	TTG	167	169	GTG	1;ND;ND	G;ND;ND	0;ND;ND	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	G113R	NONSYN	337	339	GGC	176	178	CGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	L133R	NONSYN	397	399	CTG	236	238	CGG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	D138G	NONSYN	412	414	GAC	251	253	GGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	T139M	NONSYN	415	417	ACG	254	256	ATG	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	T152S	NONSYN	454	456	ACC	293	295	TCC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	D161E	NONSYN	481	483	GAT	320	322	GAA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	R168L	NONSYN	502	504	CGT	341	343	CTT	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	E175G	NONSYN	523	525	GAA	362	364	GGA	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	527	334	folP	852	447	96.42	folP.l6.c30.ctg.2	447	0.2	0	.	p	.	0	N198S	NONSYN	592	594	AAC	431	433	AGC	ND;ND;ND	ND;ND;ND	ND;ND;ND	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	990	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3241	51.9	1	SNP	p	S91F	0	.	.	271	273	TCC	447	449	TCC	46;46;46	T;C;C	30;32;30	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	990	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3241	51.9	1	SNP	p	D95N	0	.	.	283	285	GAC	459	461	GAC	71;74;76	G;A;C	46;47;47	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	990	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	3241	51.9	1	SNP	p	D95G	0	.	.	283	285	GAC	459	461	GAC	71;74;76	G;A;C	46;47;47	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_K_01388	mtrR.WHO_K_01388	1	1	27	274	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1179	41.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	519	168	mtrR_promoter	250	82	98.8	mtrR_promoter.l15.c30.ctg.1	444	5.4	0	.	n	.	0	.206T	INS	206	206	T	39	39	T	13	T	6	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	519	168	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.2	507	38.3	0	.	n	.	0	.206T	INS	206	206	T	315	315	T	35	T	19	.	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	519	168	mtrR_promoter	250	92	98.92	mtrR_promoter.l15.c30.ctg.3	438	12.8	0	.	n	.	0	.206T	INS	206	206	T	49	49	T	22	T	10	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	770	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3057	42.7	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1698	1700	ATC	38;40;40	A;T;C,G	24;24;25,1	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	770	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3057	42.7	0	.	p	.	0	V421A	NONSYN	1261	1263	GTC	1809	1811	GCC	56;54;48	G;C;C	36;34;33	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	770	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3057	42.7	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1851	1853	GCA	48;51;51	G;C;A	32;32;29	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	770	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3057	42.7	0	.	p	.	0	I596V	NONSYN	1786	1788	ATT	2334	2336	GTT	47;47;47	G;T;T	27;26;27	.	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	770	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3057	42.7	1	SNP	p	D86N	0	.	.	256	258	GAC	804	806	GAC	61;61;60	G;A;C	36;36;36	parC.WHO_G_00206c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	770	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3057	42.7	1	SNP	p	S87R	0	.	.	259	261	AGT	807	809	AGT	60;64;66	A;G;T,C	34;38;41,1	parC.WHO_G_00206c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	770	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3057	42.7	1	SNP	p	S87I	0	.	.	259	261	AGT	807	809	AGT	60;64;66	A;G;T,C	34;38;41,1	parC.WHO_G_00206c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	770	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3057	42.7	1	SNP	p	S87W	0	.	.	259	261	AGT	807	809	AGT	60;64;66	A;G;T,C	34;38;41,1	parC.WHO_G_00206c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_G_00206c	parC.WHO_G_00206c	1	1	539	770	parC	2304	2304	99.7	parC.l6.c4.ctg.1	3057	42.7	1	SNP	p	S88P	0	.	.	262	264	TCC	810	812	TCC	66;66;62	T;C;C	39;38;35	parC.WHO_G_00206c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	746	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2610	48.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1454	1456	GGC	30;30;30	G;G;C	20;19;16	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1126	1128	GCA	101;102;101	G;C;A	54;59;58	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1129	1131	ATC	103;103;103	A;T;C	58;57;57	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1141	1143	GTG	109;109;109	G;T;G	58;59;61	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1141	1143	GTG	109;109;109	G;T;G	58;59;61	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1645	1647	ACC	76;76;76	A;C;C	39;43;46	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1699	1701	GCG	61;59;62	G;C;G	37;35;36	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1699	1701	GCG	61;59;62	G;C;G	37;35;36	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1822	1824	GGT	60;60;58	G;G;T	38;39;37	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1831	1833	GGC	50;48;48	G;G;C	33;32;31	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1016	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2125	76.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1849	1851	CCG	45;45;45	C,G;C;G	26,1;28;28	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	539	1740	ponA	2397	2397	99.92	ponA.l15.c4.ctg.1	3153	87.0	0	.	p	.	0	A375T	NONSYN	1123	1125	GCG	1481	1483	ACG	69;70;70	A;C;G	45;43;46	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	386	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1399	46.4	0	.	p	.	0	S22G	NONSYN	64	66	AGC	146	148	GGC	39;39;39	G;G;C	21;22;20	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	386	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1399	46.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	328	328	C	30	C	16	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	584	porB1b	1047	1047	97.42	porB1b.l15.c4.ctg.1	1496	63.5	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	836	838	CGA	75;75;77	C;G;A	45;44;45	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	584	porB1b	1047	1047	97.42	porB1b.l15.c4.ctg.1	1496	63.5	0	.	p	.	0	K208_I209del	DEL	622	622	A	899	899	A	89	A	49	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	584	porB1b	1047	1047	97.42	porB1b.l15.c4.ctg.1	1496	63.5	0	.	p	.	0	I218S	NONSYN	652	654	ATC	917	919	AGC	97;101;103	A;G,C;C	56;55,1;56	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	584	porB1b	1047	1047	97.42	porB1b.l15.c4.ctg.1	1496	63.5	0	.	p	.	0	A256T	NONSYN	766	768	GCA	1031	1033	ACA	101;100;87	A;C;A	56;56;49	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	584	porB1b	1047	1047	97.42	porB1b.l15.c4.ctg.1	1496	63.5	0	.	p	.	0	R257W	NONSYN	769	771	AGG	1034	1036	TGG	87;87;87	T;G;G	50;49;48	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	584	porB1b	1047	1047	97.42	porB1b.l15.c4.ctg.1	1496	63.5	0	.	p	.	0	A272V	NONSYN	814	816	GCG	1079	1081	GTA	87;85;85	G;T;A	50;49;47	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	584	porB1b	1047	1047	97.42	porB1b.l15.c4.ctg.1	1496	63.5	0	.	p	.	0	S284F	NONSYN	850	852	TCT	1115	1117	TTT	74;74;74	T;T;T	45;43;45	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	584	porB1b	1047	1047	97.42	porB1b.l15.c4.ctg.1	1496	63.5	1	SNP	p	G120K	0	.	.	358	360	GGC	635	637	GGC	76;77;77	G;G;C	41;44;44	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2522	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4798	87.9	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2032	2034	CAT	85;85;85	C;A;T	51;51;51	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	186	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	869	37.5	1	SNP	p	V57M	0	.	.	169	171	GTG	434	436	GTG	62;61;65	G,T;T;G	34,1;32;36	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
